XTL Biopharmaceuticals Ltd ADR (XTLB) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
XTL Biopharmaceuticals Ltd ADR stock (XTLB) is currently trading at $2.71. XTL Biopharmaceuticals Ltd ADR PS ratio (Price-to-Sales) is 5.70. Analyst consensus price target for XTLB is $30.00. WallStSmart rates XTLB as Sell.
- XTLB PE ratio analysis and historical PE chart
- XTLB PS ratio (Price-to-Sales) history and trend
- XTLB intrinsic value — DCF, Graham Number, EPV models
- XTLB stock price prediction 2025 2026 2027 2028 2029 2030
- XTLB fair value vs current price
- XTLB insider transactions and insider buying
- Is XTLB undervalued or overvalued?
- XTL Biopharmaceuticals Ltd ADR financial analysis — revenue, earnings, cash flow
- XTLB Piotroski F-Score and Altman Z-Score
- XTLB analyst price target and Smart Rating
XTL Biopharmaceuticals Ltd ADR
📊 No data available
Try selecting a different time range
Smart Analysis
XTL Biopharmaceuticals Ltd ADR (XTLB) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
XTL Biopharmaceuticals Ltd ADR (XTLB) Key Strengths (1)
Trading below book value, meaning the market prices it less than net assets
Supporting Valuation Data
XTL Biopharmaceuticals Ltd ADR (XTLB) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Earnings declining -76.00%, profits shrinking
Very low institutional interest at 3.58%
Micro-cap company with very limited liquidity and high volatility
Premium valuation at 5.7x annual revenue
Supporting Valuation Data
XTL Biopharmaceuticals Ltd ADR (XTLB) Detailed Analysis Report
Overall Assessment
This company scores 21/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 1 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 1.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book. Valuation metrics including Price/Book (0.97) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, EPS Growth. Some valuation metrics including Price/Sales (5.70) suggest expensive pricing. Growth concerns include EPS Growth at -76.00%, which may limit upside. Profitability pressure is visible in Return on Equity at -577.00%, Operating Margin at -854.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -577.00% needing improvement to support the investment thesis. Third, growth sustainability, with EPS Growth at -76.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
XTLB Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
XTLB's Price-to-Sales ratio of 5.70x trades at a deep discount to its historical average of 220.5x (22th percentile). The current valuation is 100% below its historical high of 1564.68x set in Aug 2021, and 5600% above its historical low of 0.1x in May 2010. Over the past 12 months, the PS ratio has compressed from ~7.5x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for XTL Biopharmaceuticals Ltd ADR (XTLB) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
XTL Biopharmaceuticals Ltd ADR operates as a stable business with moderate growth and solid fundamentals. Revenue reached 968,000 with 0% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Debt-to-equity ratio of 0.03 indicates a conservative balance sheet with 371,000 in cash.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact XTL Biopharmaceuticals Ltd ADR.
Bottom Line
XTL Biopharmaceuticals Ltd ADR offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About XTL Biopharmaceuticals Ltd ADR(XTLB)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, is engaged in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company is headquartered in Ramat Gan, Israel.